About Impulse Pharma Private Limited
Data last updated:
Impulse Pharma Private Limited is a private limited company based in Thane, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 28 October 2002 and has been in existence for over 24 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24230MH2002PTC137705. Its GSTIN is 27AABCI1460Q1ZA (Maharashtra).
The company has an authorised share capital of ₹5 Cr and a paid-up capital of ₹5 Cr. It is led by directors including Rajendra Zawar (Managing Director) and Niraj Rajendra Zawar (Managing Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at J – 201 Midctarapur Boiser, Thane, Maharashtra, India – 401506.
As per the financials filed for FY 2024, the company reported a revenue of ₹94.61 Cr, a growth of 12% compared to the previous year. For the same year it recorded a net profit of ₹8.33 Cr (net margin 8.8%) and EBITDA of ₹15.5 Cr (EBITDA margin 16.4%). Revenue has grown at a compounded annual rate (CAGR) of 15% over three years and 3% over five years.
The company has about 100 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
As per MCA filings, the company has open charges of ₹20 Cr and satisfied charges of ₹25.71 Cr on record. Court records list 2 cases involving the company, including 1 filed against it; 1 case is pending. The company has 9 deals on record (7 secondary share transfers, 2 funding rounds), with disclosed funding of ₹4.99 Cr; the latest was in April 2022. Its 10 peer companies in the Pharma industry (Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is Zyrex Healthcare Private Limited with revenue of ₹95.65 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website impulsepharma.in.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressJ – 201 Midctarapur Boiser, Thane, Maharashtra, India – 401506
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Impulse Pharma Private Limited
The main business activity of Impulse Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Impulse Pharma Private Limited FY 2025 filings available
Impulse Pharma Private Limited reported revenue of ₹94.61 Cr (up 12% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR) of Impulse Pharma Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 3% over five years, including 12% growth in the latest year. EBITDA rose 25% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Impulse Pharma Private Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | ₹94.61 Cr | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹15.5 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹8.33 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Impulse Pharma Private Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 16.4% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 8.8% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Impulse Pharma are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Impulse Pharma Private Limited
Impulse Pharma Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Zyrex Healthcare Private Limited | ₹95.65 Cr (FY 2024) | •••• | •••• | 364972.0% | •••• | Pune, Maharashtra, India |
| MCW Healthcare Private Limited | ₹95.35 Cr (FY 2024) | •••• | •••• | 16.0% | •••• | Madhya Pradesh, India |
| Surmount Laboratories Limited | ₹95.33 Cr (FY 2024) | •••• | •••• | -6.0% | •••• | Mumbai, Maharashtra, India |
| Ang Lifesciences India Limited Listed | ₹94.87 Cr (FY 2025) | •••• | •••• | -35.0% | •••• | Amritsar, Punjab, India |
| Bio-Med Private Limited | ₹94.67 Cr (FY 2025) | •••• | •••• | 19.0% | •••• | Uttar Pradesh, India |
| Impulse Pharma Private Limited this company | ₹94.61 Cr (FY 2024) | •••• | •••• | 12.0% | •••• | Thane, Maharashtra, India |
| Chiron Behring Vaccines Private Limited | ₹94.53 Cr (FY 2025) | •••• | •••• | 30.0% | •••• | Bhor, Maharashtra, India |
| Daxin Pharmaceuticals Private Limited | ₹93.78 Cr (FY 2025) | •••• | •••• | 40.0% | •••• | New Delhi, Delhi, India |
| Cosmas Research Lab Limited | ₹93.42 Cr (FY 2025) | •••• | •••• | 60.0% | •••• | Ludhiana, Punjab, India |
| Centurion Healthcare Private Limited | ₹92.65 Cr (FY 2024) | •••• | •••• | 21.0% | •••• | Vadodara, Gujarat, India |
| Lovincare Cosmetics Private Limited | ₹92.22 Cr (FY 2025) | •••• | •••• | 22.0% | •••• | Himachal Pradesh, India |
Peers are the five companies nearest above and the five nearest below Impulse Pharma by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Impulse Pharma Private Limited
Impulse Pharma Private Limited is audited by Santosh H. Barnwal for the financial year 2024.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Santosh H. Barnwal | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Impulse Pharma Private Limited
Impulse Pharma has 6 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Swapnil Vishwasrao Patil | Director | 23 Mar 2010 | 16 Years 6 Months | Current |
| Digambar Jaikishan Zawar | Director | 28 Oct 2002 | 23 Years 11 Months | Current |
| Anil Yashwantrao Patil | Director | 23 Mar 2010 | 16 Years 6 Months | Current |
| Rajendra Zawar | Managing Director | 28 Apr 2016 | 10 Years 5 Months | Current |
| Niraj Rajendra Zawar Also directs: Triofit Healthcare LLP, Triofit Nutracare Private Limited | Managing Director | 22 Feb 2023 | 3 Years 7 Months | Current |
| Pushkar Digambar Zawar Also directs: Kamla Lifesciences Limited, Kitemark Lifesciences Private Limited | Director | 28 Mar 2023 | 3 Years 6 Months | Current |
Ownership and Shareholding of Impulse Pharma Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Impulse Pharma Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Jul 2021 | Hdfc Bank Limited | ₹20 Cr | Open |
| 12 Sep 2017 | Axis Bank Limited | ₹5 Cr | Satisfied |
| 20 Mar 2013 | Others | ₹11.95 Cr | Satisfied |
| 21 Dec 2006 | Bank of Maharashtra | ₹3 Cr | Satisfied |
| 19 Dec 2006 | Bank of Maharashtra | ₹2.88 Cr | Satisfied |
Total charge records: 6 View all charges
Deals & Funding of Impulse Pharma Private Limited
Impulse Pharma Private Limited has 9 deals on record (7 secondary share transfers, 2 funding rounds), with disclosed funding of ₹4.99 Cr; the latest was in April 2022.
Deals on record (5 of 9)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Apr 2022 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Mar 2022 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Apr 2021 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Mar 2015 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 2 individuals |
| Dec 2013 | Funding round | ₹4 Cr | Investors: 4 individuals |
Full deal history
All 9 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Impulse Pharma Private Limited
Impulse Pharma Private Limited has 2 court cases on record: 1 filed against it, 1 where it is another party. 1 case is pending and 1 is disposed. Status as checked between 29 Sep 2026 and 02 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 2 | 1 | 1 |
Cases on record (2 of 2)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Mumbai City Civil Court, Maharashtra | Commercial suit | Company is another party | Pending |
| District court, Rangareddy, Telangana | Criminal complaint | Filed against the company by State of Telangana | Disposed |
Full case history
All 2 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Employees and EPFO Compliance at Impulse Pharma Private Limited
Impulse Pharma Private Limited has a workforce of 100 employees as of Sep 22, 2025.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Group Structure of Impulse Pharma Private Limited
Impulse Pharma has 1 subsidiary company and 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares Held |
|---|---|---|
| Kitemed Healthcare Private Limited | U24290MH2022PTC381279 | Locked |
Showing major subsidiaries. Total: 1.
Recent Activity on Impulse Pharma Private Limited
Impulse Pharma Private Limited has 10 board changes on record since 2002: 6 appointments and 4 cessations. The latest: Pushkar Digambar Zawar was appointed as Director on 28 Mar 2023.
16 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Impulse Pharma Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Impulse Pharma Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Impulse Pharma Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Impulse Pharma Private Limited
Impulse Pharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AABCI1460Q1ZA | Maharashtra | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Impulse Pharma Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Impulse Pharma Private Limited
Impulse Pharma is an active private limited company based in Thane, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 28 October 2002 (24+ years old) and is registered under CIN U24230MH2002PTC137705.
Impulse Pharma reported revenue of ₹94.61 Cr for FY 2024 (up 12% YoY).
Impulse Pharma has 6 current directors:
- Rajendra Zawar - Managing Director
- Niraj Rajendra Zawar - Managing Director
- Swapnil Vishwasrao Patil - Director
- Digambar Jaikishan Zawar - Director
- Anil Yashwantrao Patil - Director
- Pushkar Digambar Zawar - Director
Impulse Pharma reported a net profit of ₹8.33 Cr (net margin 8.8%) and EBITDA of ₹15.5 Cr (EBITDA margin 16.4%) for FY 2024, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Impulse Pharma is 15% over three years and 3% over five years. In the latest year (FY 2024) revenue rose 12%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Impulse Pharma is 27AABCI1460Q1ZA, registered in Maharashtra.
The CIN (Corporate Identification Number) of Impulse Pharma is U24230MH2002PTC137705. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Impulse Pharma has 2 court cases on record: 1 filed against it. 1 is pending.
Impulse Pharma was incorporated on 28 October 2002, making it 24+ years old. It is registered with the Registrar of Companies, Mumbai.
Impulse Pharma has 9 deals on record (7 secondary share transfers, 2 funding rounds), with disclosed funding of ₹4.99 Cr; the latest was in April 2022.
The peers of Impulse Pharma by revenue are Zyrex Healthcare Private Limited, MCW Healthcare Private Limited, Surmount Laboratories Limited, Ang Lifesciences India Limited, Bio-Med Private Limited and 5 more, all in the Pharma industry (Formulations).